Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBITDA: 2012-2025

Historic EBITDA for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$116.9 million.

  • Agios Pharmaceuticals' EBITDA fell 13.67% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$475.6 million, marking a year-over-year decrease of 16.86%. This contributed to the annual value of -$425.7 million for FY2024, which is 8.75% down from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' EBITDA is -$116.9 million, which was up 8.02% from -$127.1 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' EBITDA peaked at -$90.6 million during Q1 2023, and registered a low of -$127.1 million during Q2 2025.
  • Its 3-year average for EBITDA is -$106.2 million, with a median of -$105.8 million in 2024.
  • Per our database at Business Quant, Agios Pharmaceuticals' EBITDA tumbled by 111.19% in 2021 and then increased by 10.41% in 2023.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' EBITDA stood at -$104.8 million in 2021, then climbed by 5.39% to -$99.2 million in 2022, then dropped by 7.16% to -$106.3 million in 2023, then fell by 17.65% to -$125.0 million in 2024, then declined by 13.67% to -$116.9 million in 2025.
  • Its last three reported values are -$116.9 million in Q3 2025, -$127.1 million for Q2 2025, and -$106.6 million during Q1 2025.